In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro)

被引:5
|
作者
Brogi, Simone [1 ]
Rossi, Sara [2 ]
Ibba, Roberta [2 ]
Butini, Stefania [2 ]
Calderone, Vincenzo [1 ]
Campiani, Giuseppe [2 ]
Gemma, Sandra [2 ]
机构
[1] Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy
[2] Univ Siena, DoE Dept Excellence 2018 2022, Dept Biotechnol Chem & Pharm, Via Aldo Moro 2, I-53100 Siena, Italy
关键词
SARS-CoV-2; main protease (M-Pro); computer-aided drug design; molecular docking; molecular dynamics; RATIONAL DESIGN; DYNAMICS; INHIBITORS;
D O I
10.3390/computation10050069
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Despite the progress of therapeutic approaches for treating COVID-19 infection, the interest in developing effective antiviral agents is still high, due to the possibility of the insurgence of viable SARS-CoV-2-resistant strains. Accordingly, in this article, we describe a computational protocol for identifying possible SARS-CoV-2 M-pro covalent inhibitors. Combining several in silico techniques, we evaluated the potential of the peptide-based scaffold with different warheads as a significant alternative to nitriles and aldehyde electrophilic groups. We rationally designed four potential inhibitors containing difluorstatone and a Michael acceptor as warheads. In silico analysis, based on molecular docking, covalent docking, molecular dynamics simulation, and FEP, indicated that the conceived compounds could act as covalent inhibitors of M-pro and that the investigated warheads can be used for designing covalent inhibitors against serine or cysteine proteases such as SARS-CoV-2 M-pro. Our work enriches the knowledge on SARS-CoV-2 M-pro, providing a novel potential strategy for its inhibition, paving the way for the development of effective antivirals.
引用
收藏
页数:16
相关论文
共 41 条
  • [21] Synthesis of New Organoselenium-Based Succinanilic and Maleanilic Derivatives and In Silico Studies as Possible SARS-CoV-2 Main Protease Inhibitors
    Shaaban, Saad
    Al-Faiyz, Yasair S.
    Alsulaim, Ghayah M.
    Alaasar, Mohamed
    Amri, Nasser
    Ba-Ghazal, Hussein
    Al-Karmalawy, Ahmed A.
    Abdou, Aly
    INORGANICS, 2023, 11 (08)
  • [22] Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (Mpro): DFT, QSAR, molecular docking, and in silico toxicity analysis
    Mohapatra, Ranjan K.
    Perekhoda, Lina
    Azam, Mohammad
    Suleiman, Marharyta
    Sarangi, Ashish K.
    Semenets, Anton
    Pintilie, Lucia
    Al-Resayes, Saud, I
    JOURNAL OF KING SAUD UNIVERSITY SCIENCE, 2021, 33 (02)
  • [23] In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19
    Haider, Zeshan
    Subhani, Muhammad Muneeb
    Farooq, Muhammad Ansar
    Ishaq, Maryum
    Khalid, Maryam
    Akram, Muhammad Numan
    Khan, Rao Sohail Ahmad
    Niazi, Adnan Khan
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 33 (06) : 2697 - 2705
  • [24] Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19
    Adem, Sevki
    Eyupoglu, Volkan
    Ibrahim, Ibrahim M.
    Sarfraz, Iqra
    Rasul, Azhar
    Ali, Muhammad
    Elfiky, Abdo A.
    COMPUTERS IN BIOLOGY AND MEDICINE, 2022, 145
  • [25] In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2
    Abdizadeh, Rahman
    Hadizadeh, Farzin
    Abdizadeh, Tooba
    MOLECULAR DIVERSITY, 2022, 26 (02) : 1053 - 1076
  • [26] In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2
    Rahman Abdizadeh
    Farzin Hadizadeh
    Tooba Abdizadeh
    Molecular Diversity, 2022, 26 : 1053 - 1076
  • [27] Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model
    Franco, Lucas S.
    Maia, Rodolfo C.
    Barreiro, Eliezer J.
    RSC MEDICINAL CHEMISTRY, 2021, 12 (01): : 110 - 119
  • [28] Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology
    Dipta Dey
    Rajib Hossain
    Partha Biswas
    Priyanka Paul
    Md. Aminul Islam
    Tanzila Ismail Ema
    Bibhuti Kumar Gain
    Mohammad Mehedi Hasan
    Shabana Bibi
    Muhammad Torequl Islam
    Md. Ataur Rahman
    Bonglee Kim
    Molecular Diversity, 2023, 27 : 857 - 871
  • [29] Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology
    Dey, Dipta
    Hossain, Rajib
    Biswas, Partha
    Paul, Priyanka
    Islam, Md Aminul
    Ema, Tanzila Ismail
    Gain, Bibhuti Kumar
    Hasan, Mohammad Mehedi
    Bibi, Shabana
    Islam, Muhammad Torequl
    Rahman, Md Ataur
    Kim, Bonglee
    MOLECULAR DIVERSITY, 2023, 27 (02) : 857 - 871
  • [30] In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking
    Heriberto Vazquez-Mendoza, Luis
    Mendoza-Figueroa, Humberto L.
    Benjamin Garcia-Vazquez, Juan
    Correa-Basurto, Jose
    Garcia-Machorro, Jazmin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)